Moderators and participants reviewed ARANOTE, ARACOG, and ARASEC data and how they inform individualized treatment for mCSPC.
|Articles|September 30, 2022
Who is the ideal candidate to receive HIFU?
Author(s)Urology Times staff
Advertisement
In this video, Jennifer A. Linehan, MD, discusses patient selection for high-intensity focused ultrasound. Linehan is an associate professor of urology and urologic oncology at Saint John’s Cancer Institute in Santa Monica, California.
Advertisement
Related to this article
Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.
VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager entering phase 3 development for prostate cancer.
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
Based on these results, the trial protocol has been amended to move enrollment earlier in the course of disease progression.
An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
Advertisement
Advertisement
Trending on Urology Times
1
Study assesses real-world outcomes with intranasal vardenafil for ED
2
Three-year data show durable responses with mitomycin intravesical solution
3
Urocross Expander System enters US commercial use for symptomatic BPH
4
Matching mCSPC treatment to the patient, not just the trial data
5